Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
NCT00890162
- Conditions
- Anaphylaxis, Angioedema, Bronchial Diseases, +13 more
- Locations
-
- National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States